1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Intracerebral Hemorrhage - Pipeline Review, H2 2014

Intracerebral Hemorrhage - Pipeline Review, H2 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 38 pages

Intracerebral Hemorrhage - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Intracerebral Hemorrhage - Pipeline Review, H2 2014’, provides an overview of the Intracerebral Hemorrhage’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Intracerebral Hemorrhage, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Intracerebral Hemorrhage and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Intracerebral Hemorrhage
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Intracerebral Hemorrhage and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Intracerebral Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Intracerebral Hemorrhage pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Intracerebral Hemorrhage
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Intracerebral Hemorrhage pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Intracerebral Hemorrhage - Pipeline Review, H2 2014
Table of Contents

Introduction 5
Global Markets Direct Report Coverage 5
Intracerebral Hemorrhage Overview 6
Therapeutics Development 7
Pipeline Products for Intracerebral Hemorrhage - Overview 7
Pipeline Products for Intracerebral Hemorrhage - Comparative Analysis 8
Intracerebral Hemorrhage - Therapeutics under Development by Companies 9
Intracerebral Hemorrhage - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Intracerebral Hemorrhage - Products under Development by Companies 13
Intracerebral Hemorrhage - Companies Involved in Therapeutics Development 14
ActiveSite Pharmaceuticals, Inc. 14
F. Hoffmann-La Roche Ltd. 15
MediPost Co., Ltd. 16
Pfizer Inc. 17
Intracerebral Hemorrhage - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
alteplase - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
ASP-440 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
PF-05230907 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Pneumostem - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Stem Cell Therapy for Cerebral Hemorrhage - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Intracerebral Hemorrhage - Recent Pipeline Updates 34
Intracerebral Hemorrhage - Dormant Projects 35
Intracerebral Hemorrhage - Discontinued Products 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables

Number of Products under Development for Intracerebral Hemorrhage, H2 2014 7
Number of Products under Development for Intracerebral Hemorrhage - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Intracerebral Hemorrhage - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2014 14
Intracerebral Hemorrhage - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 15
Intracerebral Hemorrhage - Pipeline by MediPost Co., Ltd., H2 2014 16
Intracerebral Hemorrhage - Pipeline by Pfizer Inc., H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Intracerebral Hemorrhage Therapeutics - Recent Pipeline Updates, H2 2014 34
Intracerebral Hemorrhage - Dormant Projects, H2 2014 35
Intracerebral Hemorrhage - Discontinued Products, H2 2014 36

List of Figures

Number of Products under Development for Intracerebral Hemorrhage, H2 2014 7
Number of Products under Development for Intracerebral Hemorrhage - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Top 10 Targets, H2 2014 19
Number of Products by Stage and Top 10 Targets, H2 2014 20
Number of Products by Top 10 Mechanism of Actions, H2 2014 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 22
Number of Products by Top 10 Routes of Administration, H2 2014 23
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 24
Number of Products by Top 10 Molecule Types, H2 2014 25
Number of Products by Stage and Top 10 Molecule Types, H2 2014 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Aplastic Anemia Global Clinical Trials Review, H2, 2016

Aplastic Anemia Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • August 2016
  • by Global Data

Aplastic Anemia Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Aplastic Anemia Global Clinical Trials Review, H2, 2016" provides an overview of Aplastic Anemia clinical ...

Fanconi Anemia Global Clinical Trials Review, H2, 2016

Fanconi Anemia Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • August 2016
  • by Global Data

Fanconi Anemia Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Fanconi Anemia Global Clinical Trials Review, H2, 2016" provides an overview of Fanconi Anemia clinical ...

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • August 2016
  • by Global Data

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016" provides ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.